Novo keeps adding capacity, and jobs, to its North Carolina drug plant  

Novo Nordisk keeps adding capacity and jobs to its 457,000-square-foot finished products manufacturing plant in Clayton, North Carolina. (Novo)

Just months after announcing a $65 million expansion that will boost capacity at the North Carolina facility where it makes diabetes medications, Novo Nordisk says it needs yet more and will top it off with another $22 million and another 22 jobs.

A Novo spokesman Wednesday confirmed an announcement by development officials in Clayton, North Carolina, saying the extra money will add production lines to its 457,000-square-foot finished products manufacturing plant where it does formulation, filling and packaging of diabetes drugs.

The county is offering up some undisclosed incentives for the 22 jobs the expansion will bring, which is on top of 18 jobs tied to the $65 million investment. Novo already has more than 1,000 employees at the facility.

Free Amazon Webinar

Performing end to end real-world evidence generation in the cloud with traceability and transparency- a Sanofi journey

In this webinar you will hear about Sanofi’s journey and experience in building an industrialized big data & analytics platform in the cloud that handles billions of rows of RWD data with complete data traceability, security, and supports both traditional and advanced analytics for day to day evidence generation (RWE).

Both projects are slated to be complete by 2020, coinciding with the completion of a massive, $2 billion API facility Novo is building nearby. Novo has said the API facility, its first outside of Denmark, will need about 700 workers when it is up and running.  

The backdrop to these expansions has been significant job losses across other parts of the business of the diabetes drug specialist. CEO Lars Fruergaard Jørgensen acknowledged that job losses would tally about 1,300 this year after Novo reported that severance costs were much to blame for an 8% hit to its third quarter net profit.

Still, sales growth in the first nine months stayed positive at 4% in local currencies, to DKK 82.1 billion, mainly thanks to its GLP-1 franchise, the stalwart Victoza and brand-new longer-acting drug Ozempic.

Suggested Articles

Nearly four decades after it was approved, the FDA has ordered that heartburn drug Zantac and its generics be removed from the market.

In a non-randomized study in China, Avigan cleared virus after a median 4 days, significantly shorter than the 11 days observed for AbbVie's Kaletra.

Pfizer's 1.1-million-square-foot sterile injectables plant in Visakhapatnam has been criticized by the FDA for poor quality testing.